Learn how you can save a life. Become
an altruistic organ donor.
Plus, how do people qualify to donate? Our
donor guide explains the process.
Visit the New
England Organ Bank
The division of organ transplantation is at the forefront of critical
advances in transplantation. The center continues to be an active
participant in national and international trials evaluating the efficacy
of various drug regimes in improving outcomes, reducing rejection rates
and enhancing quality of life. The center has also recently instituted
protocols for reducing alloantibody levels in highly sensitized patients
using intravenous immunoglobulins (IVIG), plasmapheresis and anti-CD20
antibody (Rituximab). Currently, the division is involved in several
ongoing trials and employs three full-time research associates.
Reginald Y. Gohh, MD has been involved in investigating the role of
preemptive plasmapheresis in preventing recurrent FSGS in renal
transplant recipients. In collaboration with Fatemah Akhlaghi, PharmD,
PhD, of University of Rhode Island College of Pharmacy, Gohh is also
investigating the pharmacokinetics of mycophenolate mofetil in diabetic
renal transplant recipients.
Paul Morrissey, MD is interested in outcomes after renal transplantation
for organ donors and recipients. Coincident with Rhode Island Hospital's
experience in altruistic kidney donation and a large experience in
utilizing kidneys from donors after cardiac death (DCD), he has written
and lectured about safely expanding organ donation and transplantation.
Other interests include delayed allograft function and effort to limit
ischemia-reperfusion injury after transplantation.
Kevin D. Charpentier, MD's research interests include pancreas
transplantation outcomes and factors that influence early allograft
We are currently involved in a number of research studies that patients
are eligible to enter. The majority of these studies involve the use of
new or novel immunosuppressive regimens that may either enhance
transplant survival or offer a more beneficial side-effect profile.
Some topics we are currently studying include determining the level of
exercise tolerance in transplant recipients and methods to reduce the
risk of cardiovascular disease.
To learn more, call 1-401-444-8562.